Dendritic cell-based vaccines and therapies for cancer

Expert Opinion on Biological Therapy

Volumn 2, Issue 8, 2002, Pages 919-928

  Tatsumi, Tomohide ^b   Storkus, Walter J ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b NONE

Author keywords

Cancer; Dendritic cells; Vaccine

Indexed keywords

CANCER VACCINE; CD1 ANTIGEN; CD11 ANTIGEN; CD14 ANTIGEN; CD8 ANTIGEN; COMPLEMENTARY DNA; HEAT SHOCK PROTEIN; INTERLEUKIN 3; RNA; SYNTHETIC PEPTIDE; TUMOR ANTIGEN;

ANTIGEN PRESENTING CELL; AUTOIMMUNITY; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CELL FUNCTION; CELL LYSATE; CELL STIMULATION; CLINICAL TRIAL; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; DRUG MONITORING; HUMAN; IMMUNE RESPONSE; LANGERHANS CELL; MELANOMA; NONHUMAN; REVIEW; SPECIES COMPARISON; T LYMPHOCYTE;

ANIMALS; AUTOIMMUNITY; CANCER VACCINES; CLINICAL TRIALS; DENDRITIC CELLS; HUMANS; IMMUNIZATION SCHEDULE; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES;

EID: 0036909649     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2.8.919     Document Type: Review

References (123)

1. Steinmann RM: The dendritic cell system and its role in immunogenecity. Ann. Rev. Immunol. (1991) 9:271-296. This article provides an excellent review of DC biology.
2. Banchereau J, Steinmann RM: Dendritic cells and the control of immunity. Nature (1998) 392:245-252. This article provides an excellent review of DC biology.
3. Shortman K, Vremec D, Corcoran LM et al.: The linkage between T-cell and dendritic cell development in the mouse thymus. Immunol. Rev. (1998) 165:39-46.
4. Bell D, Young JW, Banchereau J: Dendritic cells. Adv. Immunol. (1999) 72:255-322.
5. Banchereau J, Briere F, Caux C et al.: Immunobiology of dendritic cells. Ann. Rev. Immunol. (2000) 18:767-811.
6. Cella M, Sallusto F, Lanzavecchia A: Origin, maturation and antigen presentation function of dendritic cells. Curr. Opin. Immunol. (1997) 9:10-16.
7. Palucka K, Banchereau J: Dendritic cells: A link between innate and adaptive immunity. J. Clin. Immunol. (1999) 19:12-25.
8. Sallusto F, Cella M, Danieli C et al.: Dendritic cells use macropinocytosis and the mannose receptor to concentrate macro-molecules in the major histocompatibilty complex class II compartment: Downregulation by cytokines and bacterial products. J. Exp Med. (1995) 182:389-400.
9. Fanger NA, Wardwell K, Shen L et al.: Type I (CD64) and Type II (CD32) Fc gamma receptor-mediated phagocytosis by human blood dendritic cells. J. Immunol. (1996) 157:541-548.
10. Fanger NA, Voigtlaender D, Lui C et al.: Characterization of expression, cytokine regulation, and effector function of the high affinity IgG receptor Fc gamma RI (CD64) expressed on human blood dendritic cells. J. Immunol. (1997) 158:3090-3098.
11. Arnold-Schild D, Hanau D, Spehner D et al.: Receptor-mediated endocytosis of heat shock protein by professional antigen-presenting cells. J. Immunol. (1999) 162:3757-3760.
12. Vabulas RM, Braedel S, Hilf N et al.: The Endoplasmic Reticulum-resident Heat Shock Protein Gp96 Activates Dendritic Cells via the Toll-like Receptor 2/4 Pathway. J. Biol. Chem. (2002) 277:20847-20853.
13. Basu S, Binder RJ, Ramalingam T et al.: CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity (2001) 14:303-313.
14. Watts C: Capture and processing of exogenous antigens for presentation on MHC molecules. Ann. Rev. Immunol. (1997) 15:821-850.
15. Sauter B, Albert ML, Francisco L et al.: Consequences of cell death: Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J. Exp. Med. (2000) 191:423-434.
16. Albert ML, Sauter B, Bhardwaj N: Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature (1998) 392:86-89.
17. Brossart P, Bevan MJ: Presentation of exogenous protein antigens on major histocompatibility complex class I molecules by dendritic cells: Pathways of presentation and regulation by cytokines. Blood (1997) 90:1594-1599.
18. Norbury CC, Chambers BJ, Prescott AR et al.: Constitutive macropinocytosis allow TAP-dependent major histocompatibility complex class I presentation of exogenous soluble antigen by bone marrow-derived dendritic cells. Eur. J. Immunol. (1997) 27:280-288.
19. Wykes M, Pombo A, Jenkins C et al.: Dendritic cells interact directly with naïve B lymphocytes to transfer antigen and initiate class switching in a primary T-dependent response. J. Immunol. (1998) 161:1313-1319.
20. Zhou LJ, Tedder TF: A distinct pattern of cytokine gene expression by human CD83+ blood dendritic cells. Blood (1995) 86:3295-3301.
21. Reddy A, Sapp M, Feldman M et al.: A monocyte conditioned medium is more effective than defined cytokines in mediating the terminal maturation of human dendritic cells. Blood (1997) 90:3640-3646.
22. Rovere P, Vallinoto C, Bondanza A et al.: Bystander apoptosis triggers dendritic cell maturation and antigen-presenting function. J. Immunol. (1998) 161:4467-4471.
23. Schuler T, Blankenstein T: Naïve CD8(+) but not CD4(+) T cells induce maturation of dendritic cells. J. Mol. Med. (2002) 80:533-541.
24. Wirths S, Reichert J, Grunebach F et al.: Activated CD8+ T-lymphocytes induce differentiation of monocytes to dendritic cells and restore the stimulatory capacity of IL-10 treated antigen presenting cells. Cancer Res. (2002) (In Press).
25. Ross R, Ross XL, Schwing J et al.: The actin-bundling protein fascin is involved in the formation of dendritic processes in maturing epidermal Langerhans cells. J. Immunol. (1998) 160:3776-3772.
26. Schwaab T, Weiss JE, Schned AR et al.: Dendritic cell infiltration in colon cancer. J. Immunother. (2001)24:130-137.
27. Chen S, Akbar SM, Tanimoto K et al.: Absence of CD83-positive mature and activated dendritic cells at cancer nodules from patients with hepatocellular carcinoma: Relevance to hepatocarcinogenesis. Cancer Lett. (2000) 148:49-57.
28. Geijtenbeek TB, Torensma R, Van Vliet SJ et al.: Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell (2000) 100:575-585.
29. Lanzavecchia A, Sallusto F: From synapses to immunological memory: The role of sustained T cell stimulation. Curr. Opin. Immunol. (2000) 12:92-98.
30. Fenton RG, Turcovski-Corrales SM, Taub DD: Induction of melanoma antigen-specific cytotoxic T lymphocytes in vitro by stimulation with B7-expressing human melanoma cell lines. J. Immunother. (1998) 2:95-108.
31. Nouri-shirazi M, Banchereau J, Fay J et al.: Dendritic cell based tumor vaccines. Immunol. Lett. (2000) 74:5-10.
32. Bjorck P: Isolation and characterization of plasmacytoid dendritic cells from Flt3 ligand and granulocyte-macrophage colony-stimulating factor-treated mice. Blood (2001) 98:3520-3526. This manuscript describes the isolation and characterisation of murine plasmacytoid DCs.
33. Inaba K, Inaba M, Romani H et al.: Generation of large numbers of dendritic cells from mouse bone marrow cultures suppl.emented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. (1992) 176:1693-1702. This work allowed for the generation of large numbers of murine DCs in vitro using culture media supplemented with GM-CSF and IL-4. These results strongly facilitated the subsequent accelerated analysis of DC immunobiology and the application of DCs in cancer treatments.
34. Ardavin C, Wu L, Li CL et al.: Thymic dendritic cells and T cells develop simultaneously in the thymus from a common precursor population. Nature (1993) 362:761-763.
35. Wu L, Li CL, Shortman K: Thymic dendritic cell precursors: Relationship to the T lymphocyte lineage and phenotype of the dendritic cell progeny. J. Exp. Med. (1996) 184:903-911.
36. Wu L, Nichogiannopoulou A, Shortman K et al.: Cell-autonomous defects in dendritic cell populations of Ikaros mutant mice point to a developmental relationship with the lymphoid lineage. Immunity (1997) 7:483-492.
37. Traver D, Akashi K, Manz M et al.: Development of CD8alpha-positive dendritic cells from a common myeloid progenitor. Science (2000) 290:2152-2154. This intriguing publication is of significantgeneral interest and documents the origin of myeloid-type DCs and the relevance of CD8α expression by DCs.
38. Manz MG, Traver D, Miyamoto T et al.: Dendritic cell potentials of early lymphoid and myeloid progenitors. Blood (2001) 97:3333-3341.
39. Wu L, D'Amico A, Winkel KD et al.: RelB is essential for the development of myeloid-related CD8alpha-dendritic cells but not of lymphoid-related CD8alpha+ dendritic cells. Immunity (1998) 9:839-847.
40. Burkly L, Hession C, Ogata L et al.: Expression of RelB is required for the development of thymic medulla and dendritic cells. Nature (1995) 373:531-536.
41. Boehmelt G, Madruga J, Dorfler P et al.: Dendritic cell progenitor is transformed by a conditional v-Rel estrogen receptor fusion protein v-RelER. Cell (1995) 80:341-352.
42. Weih F, Carrasco D, Durham SK et al.: Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-kappa B/Rel family. Cell (1995) 80:331-340.
43. Caux C, Vanbervliet B, Massacrier C et al.: CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNF alpha. J. Exp. Med. (1996) 184:695-706.
44. Caux C, Massacrier C, Vanbervliet B et al.: CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNF alpha. Adv. Exp. Med. Biol. (1997) 417:21-25.
45. De Saint-Vis B, Fugier-Vivier I, Massacrier C et al.: The cytokine profile expressed by human dendritic cells is dependent on cell subtype and mode of activation. J. Immunol. (1998) 160:1666-1676.
46. Galy A, Travis M, Cen D et al.: Human T, B, natural killer, and dendritic cells arise from a common bone marrow progenitor cell subset. Immunity (1995) 3:459-473.
47. Palucka KA, Taquet N, Sanchez-Chapui F et al.: Dendritic cells as the terminal stage of monocyte differentiation. J. Immunol. (1998) 160:4587-4595.
48. Ito T, Inaba M, Inaba K et al.: A CD1a+/CD11c+ subset of human blood dendritic cells is a direct precursor of Langerhans cells. J. Immunol. (1999) 163:1409-1419.
49. Grouard G, Rissoan MC, Filgueria L et al.: The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand. J. Exp. Med. (1997) 185:1101-1111.
50. Olweus J, Bitmansour A, Warnke R et al.: Dendritic cell ontogeny: A human dendritic cell lineage of myeloid origin. Proc. Natl. Acad, Sci. USA (1997) 94:12551-12556.
51. Rissoan MC, Soumelis V, Kadowaki N et al.: Reciprocal control of T helper cell and dendritic cell differentiation. Science (1999) 283:1183-1186.
52. Siegal FP, Kadowaki N, Shodell M et al.: The nature of the principal Type 1 interferon-producing cells in human blood. Science (1999) 284:1835-1837.
53. Cella M, Jarrossay D, Facchetti F et al.: Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of Type I interferon. Nat. Med. (1999) 5:919-923.
54. Pulendran B, Lingappa J, Kennedy MK et al.: Developmental pathways of dendritic cells in vivo: Distinct function, phenotype, and localization of dendritic cell subsets in FLT3 ligand-treated mice. J. Immunol. (1997) 159:2222-2231.
55. Pulendran B, Smith JL, Caspary G et al.: Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. Proc. Natl. Acad. Sci. USA (1999) 96:1036-1041.
56. Ohteki T, Fuako T, Suzue K et al.: Interleukin 12-dependent interferon gamma production by CD8alpha+ lymphoid dendritic cells. J. Exp. Med. (1999) 189:1981-1986.
57. Sousa CR, Hieny S, Scharton-Kersten T et al: In vivo microbial stimulation induces rapid CD40 ligand-independent production of interleukin 12 by dendritic cells and their redistribution to T cell areas. J. Exp. Med. (1997) 186:1819-1829.
58. Maldonado-Lopez R, De Smedt T, Michel P et al.: CD8alpha+ and CD8alpha-subclasses of dendritic cells direct the development of distinct T helper cells in vivo. J. Exp. Med. (1999) 189:587-592.
59. Pulendran B, Banchereau J, Burkeholder S et al.: Flt3-ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo. J. Immunol. (2000) 165:566-572.
60. Kalinski P, Hilkens CMU, Wierenga EA et al.: T-cell priming by type-1 and type-2 polarized dendritic cells: The concept of a third signal. Immunol. Today (1999) 20:561-567.
61. De Smedt T, Butz E, Maldonado-Lopez R et al.: CD8α(-) and CD8α(+) subclasses of dendritic cells undergo phenotypic and functional maturation in vitro and in vivo. J. Luekoc. Biol. (2001) 69:951-958.
62. Mayordomo JI, Zorina T, Storkus WJ et al.: Bone marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity. Nat. Med. (1995) 1:1297-1302.
63. Alters SE, Gadea JR, Philip R: Immunotherapy of cancer. Generation of CEA specific CTL using CEA peptide pulsed dendritic cells. Adv. Exp. Med. Biol. (1997) 417:519-524.
64. Traversari CP, Van Der Bruggen IF, Leuscher C et al.: A nonapeptide encode by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J. Exp. Med. (1992) 176:1453-1456.
65. Kawakami Y, Eliyahu S, Sakaguchi K et al.: Identification of the immunodominant peptides of MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med. (1994) 180:347-352.
66. Bakker ABH, Schreurs MWJ, De Boer AJ et al.: Melanocyte lineage-specific antigen gp100 is recognized by melanoma derived tumor infiltrating lymphocytes. J. Exp. Med. (1994) 179:1005-1009.
67. Tjandrawan T, Maeurer MJ, Castelli C et al.: Autologous dendritic cells pulsed with MART-1, gp100 or tyrosinase peptides elicit anti-melanoma CTL from both normal door and cancer patient peripheral blood lymphocytes in vitro. J. Immunother. (1998) 21:149-157.
68. Celluzi CM, Mayordomo JI, Storkus WJ et al.: Peptide-pulsed dendritic cells induce antigen specific CTL-mediated protective tumor immunity. J. Exp. Med. (1996) 183:283-287.
69. Brossart P, Stuhler G, Flad T et al.: Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T Lymphocytes. Cancer Res. (1998) 58:732-736.
70. Brossart P, Heinrich KS, Stuhler G et al.: Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigens for broadly applicable vaccine therapies. Blood (1999) 93:4309-4317.
71. Parkhurst MR, Salgaller ML, Southwood S et al.: Improved induction of melanoma reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J. Immunol. (1996) 157:2539-2548.
72. Amacosto AA, Prenovitz DA, Lotze MT: Rapid extracellular degradation of synthetic class I peptides by human dendritic cells. J. Immunol. (1998) 161:4023-4032.
73. Bakker AB, Marland G, De Boer AJ et al.: Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. Cancer Res. (1995) 22:5330-5334.
74. Heiser A, Coleman D, Dannull J et al.: Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J. Clin. Invets. (2002) 109:409-417.
75. Nair SK, Boczkowski D, Morse M et al.: Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected RNA. Nat. Biotechnol. (1998) 16:364-369.
76. Ashley DM, Faiola B, Nair SK et al.: Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J. Exp. Med. (1997) 186:1177-1182.
77. Boczkowski D, Nair SK, Snyder D et al.: Dendritic cells pulsed RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med. (1996) 184:465-472.
78. Jenne L, Arrighi JF, Jonuleit H et al.: Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis. Cancer Res. (2000) 60:4446-4452.
79. Albert ML, Pearce SF, Francisco LM et al.: Immature dendritic cells phagocytose apoptotic cells via αvβ5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J. Exp. Med. (1998) 188:1359-1368.
80. Fields RC, Shimizu K, Mule JJ: Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc. Natl. Acad Sci. USA (1998) 95:9482-9487.
81. Gong J, Chen D, Kashiwaba M et al.: Induction of antitumor immunity by immunization with fusion of dendritic cells and carcinoma cells. Nat. Med. (1997) 3:558-561.
82. Kugler A, Stuhler G, Walden P et al.: Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat. Med. (2000) 6:332-336.
83. Wolfers J, Lozier A, Raposo G et al.: Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat. Med. (2001) 7:297-303.
84. Zitvogel L, Regnault A, Lozier A et al.: Eradication of established murine tumors using a novel cell-free vaccine: Dendritic cell-derived exosomes. Nat. Med. (1998) 4:594-600.
85. Tuting T, Wilson CC, Martin DM et al.: Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: Enhancement by co-transfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-α. J. Immunol. (1998) 160:1139-1147.
86. Nishioka Y, Shurin M, Robbins PD et al.: Effective tumor immunotherapy using bone marrow-derived dendritic cells (DC)'s genetically engineered to express interleukin 12. J. Immunother. (1997) 20:1139-1147.
87. Nishioka Y, Hirao M, Robbins PD et al.: Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12. Cancer Res. (1999) 59:4035-4041.
88. Shimizu K, Fields RC, Giedlin M et al.: Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccine. Proc. Natl. Acad. Sci. USA (1999) 96:2268-2273.
89. Tatsumi T, Takehara T, Kanto T et al.: Administration of interleukin 12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma. Cancer Res. (2001) 61:7563-7567.
90. Lu G, Janjic BM, Janjic J et al.: Innate direct anticancer effector function of human immature dendritic cells. II. Role of TNF, Lymphotoxcin-α1β2, Fas Ligand, and TNF-related apoptosis-inducing ligand. J. Immunol. (2002) 168:1831-1839.
91. Suss G, Shortman K: A subclass of dendritic cells kills CD4 T cells via Fas/Fas-ligand-induced apoptosis. J. Exp. Med. (1996) 183:1789-1796.
92. Lu L, Quian S, Hershberger PA et al.: Fas ligand (CD95L) and B7 expression on dendritic cells provide counter-regulatory signals for T cell survival and proliferation. J. Immunol. (1997) 158:5676-5684.
93. Fanger NA, Maliszewski CR, Schooley K et al.: Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J. Exp. Med. (1999) 190:1155-1164.
94. Liu S, Yu Y, Zhang M et al.: The involvement of TNF-alpha-related apoptosis-inducing ligand in the enhanced cytotoxicity of IFN-beta-stimulated human dendritic cells to tumor cells. J. Immunol. (2001) 166:5407-5415.
95. Pulendran B, Banchereau J, Burkeholder S et al.: Flt3-ligand and granulocyte-colony stimulating factor mobilize distinct human dendritic subsets in vivo. J. Immunol. (2000) 165:566-572.
96. Lyman SD: Biology of Flt3 ligand and receptor. Int. J. Hematol. (1996) 62:63-73.
97. Brasel K, Escobar S, Anderberg R et al.: Expression of the flt3 receptor and its ligand on hematopoietic cells. Leukiemia (1995) 9:1212-1218.
98. Lynch DH: Induction of dendritic cells (DC) by Flt3 ligand (FL) promotes the generation of tumor-specific immune responses in vivo. Crit. Rev. Immunol. (1998) 18:99-107.
99. Maraskovsky E, Brasel K, Teepe K et al.: Dramatic increase in the number of functional mature dendritic cells in Flt3 ligand-treated mice: Multiple dendritic cell subpopulations identified. J. Exp. Med. (1996) 184:1953-1962.
100. Lynch DH, Andreasen A, Maraskovsky et al.: Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nat. Med. (1997) 3:625-631.
101. Pulendran B, Lingappa J, Kennedy MK et al.: Development pathways of dendritic cells in vivo: Distinct function, phenotype, and localization of dendritic cell subsets in FLT3 ligand-treated mice. J. Immunol. (1997) 159:2222-2231.
102. Gilboa E: The risk of autoimmunity associated with tumor immunotherapy. Nat. Immunol. (2001) 2:789-792. This article provides a good overview of autoimmunity that may result from DC-based vaccinations.
103. Ludewig B, Ochsenbein AF, Odermatt B et al.: Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells resulted in severe autoimmune disease. J. Exp. Med. (2000) 191:795-803.
104. Overwijk WW, Lee DS, Surman DR et al.: Vaccination with a recombinant vaccinia virus encoding a 'self' antigen induces autoimmune vilitigo and tumor cell destruction in mice: Requirement of CD4+ T lymphocytes. Proc. Natl. Acad. Sci. USA (1999) 96:2982-2987.
105. Nestle FO, Alijagic S, Gilliet M et al.: Vaccination of melanoma patients with peptide- or tumor lysates-pulsed dendritic cells. Nat. Med. (1998) 4:328-32. This manuscript reports details of the first clinical trial data in melanoma patients treated with DC-based therapeutic vaccines.
106. Thurner B, Haendle I, Roder C et al.: Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. (1999) 190:1669-1678.
107. Schuler-Thurner B, Dieckmann D, Keikavoussi P et al.: Mage-3 and influenza-matrix peptide-specific cytotxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells. J. Immunol. (2000) 165:3492-3496
108. Mackensen A, Herbst B, Chen JL et al.: Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34+ hematopoietic progenitor cells. Int. J. Cancer (2000) 86:385-392.
109. Nair SK, Hull S, Coleman D et al.: Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocytes responses in vitro using autologous dendritic cells loaded with CEA peptides or CEA RNA in patients with metastatic malignancies expressing CEA. Int. J. Cancer (1999) 82:121-124.
110. Murphy GP, Tjoa BA, Simmonds SJ et al.: Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: A Phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate (1999) 38:73-78.
111. Hsu FJ, Benike C, Fagnoni F et al.: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. (1996) 2:52-58. This is the first clinical report of a human DC-based vaccine. This trial was performed in the setting of B-cell lymphoma using DCs pulsed with the patient's own tumour-associated immunoglobulin idiotype protein as the cancer antigen.
112. Reichardt VL, Okada CY, Liso A et al.: Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell cefl transplantation for multiple myeloma-a feasibility study. Blood (1999) 93:2411-2419.
113. Brosssart P, Wirths S, Stuhler G et al.: Induction of cytotoxic T-lymphocyte responses in vivo after vaccination with peptide-pulsed dendritic cells. Blood (2000) 96:3102-3108.
114. Kikuchi T, Akasaki Y, Irie M et al.: Results of a Phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol. Immunother. (2001) 50:337-344.
115. Yu JS, Wheeler CJ, Zeltzer PM et al.: Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T cell infiltration. Cancer Res. (2001) 61:842-847.
116. Keilholz U, Weber J, Finke JH et al.: Immunologic monitoring of cancer vaccine therapy. J. Immunother. (2002) 25:97-138. This review provides significant insight into the available state-of-the-art techniques used to monitor the tumour-specific immune response in cancer patients treated with immunotherapy.
117. Asai T, Storkus WJ, Whiteside TL: Evaluation of the modified ELISPOT assay for interferon production in cancer patients receiving antitumor vaccine. Clin. Diagn. Lab. Immunol. (2000) 7:145-154.
118. Pardoll DM, Topalian SL: The role of CD4+ T cell responses in antitumor immunity. Curr. Opin. Immunol. (1998) 10:588-594.
119. Toes RE, Ossendrop F, Offringa R et al.: CD4+ T cells and their role in antitumor immune responses. J. Exp. Med. (1999) 189:753-756.
120. Jager E, Nagata Y, Gnjatic S et al.: Monitoring CD8 T cell responses to NY-ESO-1: Correlation of humoral and cellular immune responses. Proc. Natl. Acad. Sci. USA (2000) 97:4760-4765.
121. Yee C, Savage PA, Lee PP et al.: Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J. Immunol. (1999) 162:2227-2234.
122. Romero P, Dunbar PR, Valmori D et al.: Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J. Exp. Med. (1998) 188:1641-1650.
123. Skinner PJ, Daniels MA, Schmidt CS et al.: Cutting edge: In situ tetramer staining of antigen-specific T cells in tissues. J. Immunol. (2000) 165:613-617.